Development of whole blood and serum microsampling LC/MS/MS methods for clinical analysis  with a goal towards point-of-care therapeutic drug monitoring

Daniel B Kassel

Development of whole blood and serum microsampling LC/MS/MS methods for clinical analysis with a goal towards point-of-care therapeutic drug monitoring

Daniel B Kassel

Sci Analytical Strategies Inc., USA

: J Diagn Tech Biomed Anal

Abstract

W hole blood microsampling is emerging as an attractive, alternate approach to the invasive vena-puncture, large volume blood conventional method for clinical diagnostics testing. One explanation for this paradigm shift is the vast improvement in sensitivity and ease of use of high performance triple quadrupole and QTOF mass spectrometers introduced recently. In this poster, we present two methods Ã¢Â€Â“ micro-serum processing and a new whole blood microsampler method, Mitra. These methods are evaluated for their potential to aid in personalized medicine and individual therapeutic drug monitoring. For personalized medicine, we show the power of the technology and its application to vitamin D testing. For therapeutic drug monitoring, opiates are chosen for this evaluation as the model analyte class. In the arena of illicit drug use, therapeutic drug monitoring can provide a mechanism for improved compliance or more appropriate titrating of dose to achieve the pharmacological effect. Late phase development of centrally acting analgesics is complicated by the risk of opioid diversion or abuse and therefore requires monitoring of opioid study drugs and any concomitant opioids. Traditional compliance monitoring is performed using urine samples; however, there is a high risk of urine sample adulteration and urine drug levels are difficult to interpret pharmacologically. In this poster, we present preliminary data using a whole blood microsampling device that has the potential for therapeutic drug monitoring.